Description

ELTROXIN 75 MG (1X120)

Indications

ELTROXIN 75 MG is primarily indicated for the treatment of hypothyroidism, a condition where the thyroid gland does not produce enough thyroid hormones. It is also used in the management of goiter, thyroid cancer, and as a replacement therapy following thyroidectomy. Additionally, ELTROXIN may be prescribed for certain types of congenital hypothyroidism.

Mechanism of Action

ELTROXIN contains levothyroxine sodium, a synthetic form of thyroxine (T4), which is a hormone produced by the thyroid gland. Once administered, levothyroxine is converted into triiodothyronine (T3), the active form of thyroid hormone. These hormones play a crucial role in regulating the body’s metabolism, influencing growth and development, and maintaining normal physiological functions. By restoring the levels of thyroid hormones in the body, ELTROXIN helps alleviate the symptoms associated with hypothyroidism, such as fatigue, weight gain, and depression.

Pharmacological Properties

Levothyroxine sodium is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 2 to 4 hours after oral administration. The bioavailability of ELTROXIN can be affected by various factors, including the presence of food, gastrointestinal transit time, and the formulation of the drug. The half-life of levothyroxine is approximately 7 days, allowing for once-daily dosing in most patients. The drug is primarily metabolized in the liver and excreted in urine, with a small fraction eliminated in feces.

Contraindications

ELTROXIN is contraindicated in patients with a known hypersensitivity to levothyroxine or any of the excipients in the formulation. It should not be used in individuals with untreated adrenal insufficiency, acute myocardial infarction, or thyrotoxicosis. Caution is advised when prescribing ELTROXIN to patients with cardiovascular diseases, as the drug can increase heart rate and myocardial oxygen demand.

Side Effects

Common side effects of ELTROXIN may include headache, insomnia, nervousness, and palpitations. More serious adverse reactions can occur, particularly if the dosage is too high, leading to symptoms of hyperthyroidism such as weight loss, increased appetite, heat intolerance, and menstrual irregularities. Long-term use of levothyroxine may also result in decreased bone mineral density, increasing the risk of osteoporosis and fractures, particularly in postmenopausal women.

Dosage and Administration

The dosage of ELTROXIN must be individualized based on the patient’s age, weight, clinical response, and laboratory findings. For adults with hypothyroidism, the typical starting dose is 1.6 micrograms per kilogram of body weight per day, which may be adjusted based on thyroid function tests. For elderly patients or those with underlying cardiovascular conditions, a lower starting dose of 12.5 to 25 micrograms per day is recommended, with gradual increases as tolerated. ELTROXIN should be taken on an empty stomach, ideally 30 to 60 minutes before breakfast, to enhance absorption.

Interactions

ELTROXIN may interact with various medications and substances, potentially altering its effectiveness or increasing the risk of side effects. Drugs that may decrease the absorption of levothyroxine include antacids, calcium supplements, iron supplements, and certain cholesterol-lowering agents. Additionally, medications such as warfarin may have their effects potentiated when used concurrently with ELTROXIN, necessitating careful monitoring of coagulation parameters. It is essential for patients to inform their healthcare provider of all medications and supplements they are taking to avoid potential interactions.

Precautions

Before initiating treatment with ELTROXIN, a thorough medical history and physical examination should be conducted. Patients with pre-existing cardiovascular conditions, diabetes, or adrenal insufficiency should be closely monitored during treatment. Regular follow-up visits are important to assess thyroid function and adjust the dosage as needed. Pregnant and breastfeeding women should use ELTROXIN with caution, as thyroid hormone levels can affect fetal and neonatal development. It is crucial to maintain appropriate thyroid hormone levels during pregnancy to support the health of both the mother and the developing fetus.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy and safety of levothyroxine in managing hypothyroidism. A systematic review published in the Journal of Clinical Endocrinology & Metabolism highlighted that levothyroxine replacement therapy significantly improves quality of life and alleviates symptoms in patients with hypothyroidism. Another study in the Thyroid journal emphasized the importance of individualized dosing to achieve optimal thyroid hormone levels, thereby minimizing the risk of adverse effects associated with overtreatment or undertreatment.

Conclusion

ELTROXIN 75 MG is a vital medication for individuals suffering from hypothyroidism and other thyroid-related conditions. Its active ingredient, levothyroxine sodium, effectively restores thyroid hormone levels, leading to improved metabolic function and overall well-being. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for safe and effective treatment. Regular monitoring and individualized dosing are critical components of successful therapy with ELTROXIN.